[go: up one dir, main page]

MX2017007676A - Nuevos compuestos. - Google Patents

Nuevos compuestos.

Info

Publication number
MX2017007676A
MX2017007676A MX2017007676A MX2017007676A MX2017007676A MX 2017007676 A MX2017007676 A MX 2017007676A MX 2017007676 A MX2017007676 A MX 2017007676A MX 2017007676 A MX2017007676 A MX 2017007676A MX 2017007676 A MX2017007676 A MX 2017007676A
Authority
MX
Mexico
Prior art keywords
novel compounds
therapy
relates
neutrophil elastase
inhibitory properties
Prior art date
Application number
MX2017007676A
Other languages
English (en)
Inventor
Rizzi Andrea
Armani Elisabetta
Capaldi Carmelida
Andrew Heald Robert
Mark Sutton Jonathan
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2017007676A publication Critical patent/MX2017007676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a derivados de imidazolona que tienen propiedades inhibitorias contra la elastasa de neutrófilos humana, y su uso en terapia.
MX2017007676A 2014-12-15 2015-12-11 Nuevos compuestos. MX2017007676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14198044 2014-12-15
PCT/EP2015/079371 WO2016096638A1 (en) 2014-12-15 2015-12-11 Novel compounds

Publications (1)

Publication Number Publication Date
MX2017007676A true MX2017007676A (es) 2017-10-27

Family

ID=52133873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007676A MX2017007676A (es) 2014-12-15 2015-12-11 Nuevos compuestos.

Country Status (12)

Country Link
US (1) US9409870B2 (es)
EP (1) EP3233833B1 (es)
KR (1) KR20170095262A (es)
CN (1) CN107108577A (es)
AR (1) AR102967A1 (es)
BR (1) BR112017012608A2 (es)
CA (1) CA2970664A1 (es)
MX (1) MX2017007676A (es)
RU (1) RU2017120277A (es)
TR (1) TR201907044T4 (es)
TW (1) TW201629040A (es)
WO (1) WO2016096638A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ747313A (en) * 2016-05-31 2020-01-31 Chiesi Farm Spa Imidazolone compounds as human neutrophil elastase inhibitors
EP3464268B1 (en) * 2016-05-31 2020-03-11 Chiesi Farmaceutici S.p.A. Novel compounds
AR108609A1 (es) * 2016-05-31 2018-09-05 Chiesi Farm Spa Derivados de imidazolona y pirazolona como inhibidores de la elastasa de neutrófilos humana (hne)
CN114667590B (zh) 2019-09-25 2025-03-25 印地安纳大学理事会 用于脉冲模式电荷检测质谱法的设备和方法
CN114728237A (zh) 2019-10-10 2022-07-08 印地安纳大学理事会 用于识别、选择和纯化粒子的系统和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2740728A4 (en) 2011-08-01 2015-04-01 Sumitomo Dainippon Pharma Co Ltd URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
WO2014009425A1 (en) 2012-07-12 2014-01-16 Chiesi Farmaceutici S.P.A. Inhibition of enzymes

Also Published As

Publication number Publication date
BR112017012608A2 (pt) 2018-01-16
US9409870B2 (en) 2016-08-09
TR201907044T4 (tr) 2019-06-21
KR20170095262A (ko) 2017-08-22
WO2016096638A1 (en) 2016-06-23
CN107108577A (zh) 2017-08-29
CA2970664A1 (en) 2016-06-23
US20160168101A1 (en) 2016-06-16
EP3233833A1 (en) 2017-10-25
EP3233833B1 (en) 2019-02-20
RU2017120277A (ru) 2019-01-17
AR102967A1 (es) 2017-04-05
TW201629040A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
PH12015501043A1 (en) Novel compounds
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2022001105A (es) Anticuerpos anti tigit.
PH12016501702A1 (en) Pyrazole amide derivative
IL276733A (en) Use of Aribolin in cancer treatment
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX2017007188A (es) Compuesto antimicotico.
MX2017007676A (es) Nuevos compuestos.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2016016371A (es) Nuevos compuestos.
MX2016016381A (es) Derivados de tetrahidrotriazolopirimidina, composiciones farmaceuticas que contienen los mismos y usos.
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
GB2546703A (en) Compounds
HK1257141A1 (en) Varlitinib for use in the treatment of resistant or refractory cancer
HK1242961A1 (en) Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
HK1242961A (en) Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases